Di seguito sono riportate le informazioni acquisite su CELGENE CORP, che non è ancora inclusa nel nostro perimetro di ricerca.

Per richiedere una valutazione di questa azienda e l'inserimento nel Ranking OpenCorporation o se hai dati ulteriori, diversi e più aggiornati di quanto pubblicato in questa scheda aziendale OpenCorporation, scrivi a info@opencorporation.org così che il nostro team possa tenerne conto.

Aggiornato il 8 luglio 2023

Descrizione attività
(disponibile solo in inglese)

Research and experimental development on biotechnology (NACE2 7211)

This company operates as an American integrated biopharmaceutical firm that specialises in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immunological diseases through regulation of genomic and proteomic targets. It was established in 1986. Its corporate headquarters is located in Summit, New Jersey. The company is a global leader in biotechnology. It produces drug therapies for cancer and inflammatory disorders with the goal of delivering quality results for better healthcare. Its products include REVLIMID (lenalidomide), THALOMID (thalidomide), ALKERAN (melphalan), FOCALIN (dexmethylphenidate HCl) cellular and tissue therapeutics, as well as the RITALIN family of drugs. REVLIMID is used for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk MDS (myelodysplastic syndromes) associated with a deletion 5q cytogenetic abnormality. The THALOMID is approved for the treatment of certain conditions associated with Erythema Nodosum Leprosum (ENL) and for newly diagnosed multiple myeloma patients. ALKERAN was in-licensed from GlaxoSmithKline for the treatment of multiple myeloma. RITALIN and FOCALIN are used as a treatment of attention deficit disorder and attention deficit hyperactivity disorder (ADHD) in children and adolescents. The company focuses on putting patients first through helping to provide a broad access of its innovative therapies' clinical benefits. It created a resource healthcare provider called Patient Support Solutions (PSS). The PSS program allows healthcare provider to inquire about and arrange for reimbursement and insurance assistance. The company has a collaborative agreement with Novartis Pharma AG for the development and commercialization of FOCALIN XRTM.

  • CELGENE CORP

  • United States of America (US)
  • Tipo di azienda: Corporate
  • Impresa controllante: BRISTOL-MYERS SQUIBB COMPANY
  • Amministratore Delegato (CEO): Dr. Giovanni Caforiomd
  • Compenso Amministratore Delegato: N/D
  • Sito web: www.celgene.com

Parametri finanziari

Numero di dipendenti

N/D
N/D
N/D
N/D

Fatturato 1

N/D
N/D
N/D
N/D

EBIT 1

N/D
N/D
N/D
N/D

EBITDA 1

N/D
N/D
N/D
N/D

1 numeri espressi in milioni

  • RepRisk indicator (ultimo mese):  5

Dialogo sociale

  • Transnational Corporate Agreement (TCA): N/D
  • Global Framework Agreement (GFA): N/D
  • Societas Europaea (SE): N/D
  • Bangladesh Accord: N/D

Comitati Aziendali Europei

  • CAE: N/D

Standard e certificazioni

  • Global Compact: N/D
  • CDP (Carbon Disclosure Project): N/D
  • Modern Slavery Statement: N/D
  • Transparency Index: N/D
  • SA8000 Social Accountability: N/D
  • Bilancio Integrato: N/D
  • ISO26000: N/D
  • Linee Guida Ocse: N/D
  • Social Development Goals (SDGs):

Certificazione Global Reporting Initiative

  • Global Reporting Initiative standards:
  • Global Reporting Initiative GRI G4: N/D

Altre dichiarative aziendali

  • Responsabilità sociale d'impresa:
    N/D
  • Accessibilità: N/D

Policy

  • Policy sulla formazione:
  • Policy a tutela del diritto alla salute e alla sicurezza nei luoghi di lavoro dove opera l'azienda:
  • Policy a tutela del diritto alla salute e alla sicurezza nei luoghi di lavoro lungo filiera:
  • Policy sulla diversità:

Dichiarazioni universali

Dichiarazioni e trattati riconosciuti dal paese in cui l'azienda ha la sede legale

  • Dichiarazione universale dei Diritti Umani:
  • Convenzione europea dei diritti dell'uomo (CEDU):
  • Carta dei Diritti Fondamentali dei Lavoratori CDFL (Carta di Strasburgo 1989):
  • Carta dei diritti fondamentali dell'Unione Europea CDF UE (Carta di Nizza 2000):
  • Trattato sul funzionamento dell'Unione europea TFUE:
  • Sede legale in un Paese OCSE:
  • ILO C029 - Forced Labour Convention, 1930 (No. 29):
  • ILO C087 - Freedom of Association and Protection of the Right to Organise Convention, 1948 (No. 87):
  • ILO C098 - Right to Organise and Collective Bargaining Convention, 1949 (No. 98):
  • ILO C100 - Equal Remuneration Convention, 1951 (No. 100):
  • ILO C105 - Abolition of Forced Labour Convention, 1957 (No. 105):
  • ILO C111 - Discrimination (Employment and Occupation) Convention, 1958 (No. 111):
  • ILO C138 - Minimum Age Convention, 1973 (No. 138):
  • ILO C182 - Worst Forms of Child Labour Convention, 1999 (No. 182):

Direttive applicate alle sedi nella UE 27

  • D. 80/987/EEC: N/D
  • D. 89/391/EEC: N/D
  • D. 98/59/EC: N/D
  • D. 2000/43/EC: N/D
  • D. 2000/78/EC: N/D
  • D. 2001/23/EC: N/D
  • D. 2001/86/EC del Consiglio: N/D
  • D. 2002/14/EC: N/D
  • D. 2002/73/EC: N/D
  • D. 2003/72/EC del Consiglio: N/D
  • D. 2005/56/EC del PE e del Consiglio: N/D
  • D. 2009/38/EC: N/D
  • D. 2004/25/EC: N/D
  • D. 2011/35/EU: N/D

Presenza nei principali ranking

  • Global 100 Most Sustainable Corporations: N/D
  • Global CSR Rep Trak 100: N/D
  • BrandZ Top 100 Most Valuable US Brands: N/D
  • The Worlds Best Multinational Workplaces: N/D
  • The Gartner Supply Chain Top 25: N/D
  • The Worlds Most Innovative Companies: N/D
  • The Diversity Inc Top 50 Companies: N/D
  • Best Global Websites: N/D
  • Green Ranking Global Top 500: N/D
  • Green Ranking Global Top 100: N/D

Sindacati di riferimento